SG/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25

SG/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25 Share Price

DE000SQ86UF9

Market Closed - Deutsche Boerse AG 01:12:04 01/06/2024 am IST
0.002 ^EUR	-.--%

1 month	-60.00%
3 months	-92.31%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	05:30pm	RE
GSK blood cancer drug nearly halves risk of death in late-stage trial	05:30pm	RE
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	01/06	BU
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	30/05	MT

More news

Quotes 5-day view

Date	Price	Change
31/24/31	0.002	-.--%
30/24/30	0.002	-.--%
29/24/29	0.002	+100.00%
28/24/28	0.001	-80.00%
27/24/27	0.005	+25.00%

Delayed Quote Deutsche Boerse AG

Last update May 01, 2024 at 01:12 am IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SQ86UF
ISIN	DE000SQ86UF9
Date issued	16/02/2023
Strike	75 $
Maturity	17/01/2025 (229 Days)
Parity	10 : 1
Emission price	0.9 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.85 €
Lowest since issue	0.001 €
Spread	0.018 €
Spread %	90.00%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus